Collegium Pharmaceutical (COLL) Set to Announce Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $1.52 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company's conference call can do so using this link.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm's revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.13 earnings per share. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Down 1.5 %

Shares of NASDAQ:COLL traded down $0.53 during trading on Thursday, hitting $34.14. 181,486 shares of the company were exchanged, compared to its average volume of 438,855. The firm's 50 day moving average price is $37.60 and its 200-day moving average price is $35.29. The stock has a market capitalization of $1.12 billion, a P/E ratio of 14.45 and a beta of 0.94. Collegium Pharmaceutical has a 12-month low of $21.40 and a 12-month high of $42.29. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04.

Insiders Place Their Bets

In other news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

COLL has been the subject of a number of research analyst reports. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Piper Sandler reiterated a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Truist Financial raised their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Finally, HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.